# FLT3LG

## Overview
FLT3LG, or fms-related receptor tyrosine kinase 3 ligand, is a gene that encodes a cytokine involved in the regulation of hematopoiesis and immune system development. The protein product, FLT3 ligand, is a crucial component in the signaling pathways that govern the proliferation and differentiation of hematopoietic progenitor cells. It functions by binding to the FLT3 receptor, a type III receptor tyrosine kinase, which is predominantly expressed on hematopoietic stem cells and early progenitors. This interaction activates key signaling cascades, including the PI3K/AKT and RAS/RAF/MEK/ERK pathways, which are essential for cellular proliferation and survival (Verstraete2011Structural; Marensi2021Pharmacological). FLT3 ligand exists in both membrane-bound and soluble forms, with the latter being generated through proteolytic cleavage, which modulates its function within the hematopoietic system (Horiuchi2009Ectodomain). The FLT3LG gene and its protein product play significant roles in immune responses, particularly in the activation and expansion of dendritic and natural killer cells, and have been implicated in various pathological conditions, including acute myelocytic leukemia (AML) (Cueto2021The; Chen2022FLT3LG).

## Structure


## Function
The FLT3LG gene encodes the FLT3 ligand, a cytokine crucial for hematopoiesis, the process of blood cell formation. FLT3 ligand primarily functions by binding to the FLT3 receptor, a type III receptor tyrosine kinase, which is expressed on hematopoietic stem cells and early progenitors. This interaction activates signaling pathways such as PI3K/AKT and RAS/RAF/MEK/ERK, which are essential for the proliferation and differentiation of hematopoietic progenitor cells (Verstraete2011Structural; Marensi2021Pharmacological).

In healthy human cells, FLT3 ligand is expressed in CD4+ and CD8+ T cells, while its receptor is mainly found on dendritic cells. This interaction is important for dendritic cell activation, as evidenced by the correlation between FLT3LG expression and CD40, a marker of dendritic cell activation (Chen2022FLT3LG). The FLT3 ligand also plays a role in the development and expansion of natural killer cells and dendritic cells, which are vital for immune responses (Verstraete2011Structural).

FLT3 ligand exists in both membrane-bound and soluble forms, with the latter being generated through proteolytic cleavage by TNF-α converting enzyme (TACE), which regulates its availability and function in the hematopoietic system (Horiuchi2009Ectodomain).

## Clinical Significance
Alterations in the expression level of the FLT3LG gene have significant clinical implications, particularly in the context of acute myelocytic leukemia (AML). FLT3LG is downregulated in AML samples, and its expression is associated with the overall survival rate of AML patients. The study by Chen et al. identified FLT3LG as a hub gene significantly associated with the prognosis of AML, suggesting that its reduced expression may contribute to poorer outcomes (Chen2022FLT3LG). FLT3LG is also involved in immune activity within the tumor microenvironment, particularly in the activation of CD4+ and CD8+ T cells, which are crucial for effective immune responses against tumor cells (Chen2022FLT3LG).

FLT3LG's interaction with the FLT3 receptor is crucial for dendritic cell activation, which is important for initiating immune responses. In AML, the expression of FLT3LG is significantly reduced, potentially affecting dendritic cell function and T cell activity in the bone marrow microenvironment (Chen2022FLT3LG). The study also highlights the role of FLT3LG in the NOTCH signaling pathway, which is known to activate T cells, further emphasizing its importance in immune regulation and potential impact on AML progression (Chen2022FLT3LG).

## Interactions
FLT3LG, or fms-related receptor tyrosine kinase 3 ligand, primarily interacts with the FLT3 receptor, a type III receptor tyrosine kinase. This interaction is crucial for the activation of signaling pathways involved in hematopoiesis and immune system development. FLT3LG binds bivalently to the D3 domain of two FLT3 monomers, facilitating receptor dimerization, which is essential for receptor activation and subsequent signaling cascades (Marensi2021Pharmacological). The binding of FLT3LG to FLT3 initiates signaling pathways such as the phosphoinositide 3 kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways, which are involved in cell proliferation and survival (Marensi2021Pharmacological).

FLT3LG is expressed in CD4+ and CD8+ T cells, while its receptor, FLT3, is mainly found in dendritic cells. The interaction between FLT3LG and FLT3 is associated with dendritic cell activation, as indicated by increased CD40 expression, a marker of dendritic cell activation (Chen2022FLT3LG). This interaction is also implicated in the expansion of various bone marrow progenitor populations, leading to the differentiation of multiple cell types (Cueto2021The). The FLT3LG-FLT3 axis plays a significant role in both normal physiological conditions and pathological states such as acute myelocytic leukemia (AML) (Chen2022FLT3LG).


## References


[1. (Cueto2021The) Francisco J. Cueto and David Sancho. The flt3l/flt3 axis in dendritic cell biology and cancer immunotherapy. Cancers, 13(7):1525, March 2021. URL: http://dx.doi.org/10.3390/cancers13071525, doi:10.3390/cancers13071525. This article has 73 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13071525)

[2. (Marensi2021Pharmacological) Vanessa Marensi, Karen R. Keeshan, and David J. MacEwan. Pharmacological impact of flt3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors. Biochemical Pharmacology, 183:114348, January 2021. URL: http://dx.doi.org/10.1016/j.bcp.2020.114348, doi:10.1016/j.bcp.2020.114348. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bcp.2020.114348)

[3. (Chen2022FLT3LG) Haiyan Chen, Meng Wu, Hongping Xia, Songjie Du, Guoren Zhou, Guangfeng Long, Yanan Zhu, Xu Huang, and Daheng Yang. Flt3lg and ifitm3p6 consolidate t cell activity in the bone marrow microenvironment and are prognostic factors in acute myelocytic leukemia. Frontiers in Immunology, August 2022. URL: http://dx.doi.org/10.3389/fimmu.2022.980911, doi:10.3389/fimmu.2022.980911. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.980911)

[4. (Horiuchi2009Ectodomain) Keisuke Horiuchi, Hideo Morioka, Hironari Takaishi, Haruhiko Akiyama, Carl P. Blobel, and Yoshiaki Toyama. Ectodomain shedding of flt3 ligand is mediated by tnf-α converting enzyme. The Journal of Immunology, 182(12):7408–7414, June 2009. URL: http://dx.doi.org/10.4049/jimmunol.0801931, doi:10.4049/jimmunol.0801931. This article has 28 citations.](https://doi.org/10.4049/jimmunol.0801931)

[5. (Verstraete2011Structural) Kenneth Verstraete, Gonzalez Vandriessche, Mariska Januar, Jonathan Elegheert, Alexander V. Shkumatov, Ambroise Desfosses, Kathleen Van Craenenbroeck, Dmitri I. Svergun, Irina Gutsche, Bjorn Vergauwen, and Savvas N. Savvides. Structural insights into the extracellular assembly of the hematopoietic flt3 signaling complex. Blood, 118(1):60–68, July 2011. URL: http://dx.doi.org/10.1182/blood-2011-01-329532, doi:10.1182/blood-2011-01-329532. This article has 71 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2011-01-329532)